|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 403/12 | (2006.01) |
| A61K 31/495 | (2006.01) | ||
| A61K 31/505 | (2006.01) |
| (11) | Number of the document | 2964638 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14710620.7 |
| Date of filing the European patent application | 2014-03-05 | |
| (97) | Date of publication of the European application | 2016-01-13 |
| (45) | Date of publication and mention of the grant of the patent | 2017-08-09 |
| (46) | Date of publication of the claims translation | 2017-12-27 |
| (86) | Number | PCT/GB2014/050655 |
| Date | 2014-03-05 |
| (87) | Number | WO 2014/135876 |
| Date | 2014-09-12 |
| (30) | Number | Date | Country code |
| PCT/CN2013/0722 | 2013-03-06 | WO |
| (72) |
LI, David, Yunzhi, CN
WANG, Jiabing, CN
YANG, Zhenfan, CN
ZENG, Qingbei, CN
ZHANG, Xiaolin, CN
|
| (73) |
Astrazeneca AB,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai |
| QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR |
| Payment date | Validity (years) | Amount | |
| 2026-01-21 | 13 | 289.00 EUR |
| 2027-03-05 |